Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
4
×
national blog main
boston
deals
national top stories
alexion pharmaceuticals
autoimmune disorders
fda
sanofi
allosteric
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
atlas venture
atopic dermatitis
boehringer ingelheim
brace pharma
cancer
cancer drugs
cleva pharma
colorectal cancer
complement system
dicerna pharamceuticals
drug discovery
dupilumab
generalized myasthenia gravis
glaxosmithkline
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
hotspot therapeutics
immune-mediated necrotizing myopathy
investing
ipo
jonathan montagu
mark goldsmith
metabolic diseases
What
disease
4
×
medicines
4
×
drug
pharma
pharmaceuticals
potential
research
address
adds
ago
allosteric
alternative
autoimmune
cancer
cancer’s
candidate
caught
causing
clinic
deal
dicerna
elusive
expensive
eye
frontiers
gene
hepatitis
hotspot
intended
ipo
known
lead
maps
molecules
new
parlance
path
pay
pharmaceutical
play
Language
unset
4
×
Current search:
medicines
×
photo
×
" life sciences "
×
disease
×
unset
×
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma